Highlights GuiZhou SanLi Pharmaceutical Co.,Ltd

Equities

603439

CNE1000040B4

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 27/05/2024 am IST			5-day change	1st Jan Change
15.42 ^CNY	+2.05%		-2.22%	-18.33%

26/04	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
26/04	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04	CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	27/04	CI
Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 4, 2023.	09/12	CI
Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on November 4, 2023, has closed with 1,550,900 shares, representing 0.38% for CNY 29.99 million.	07/12	CI
Guizhou Sanli Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 40 million worth of its shares.	04/11	CI
Guizhou Sanli Pharmaceutical Co.,Ltd authorizes a Buyback Plan.	03/11	CI
Guizhou Sanli Pharmaceutical Co.,Ltd completed the acquisition of 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian.	30/23/30	CI
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. completed the acquisition of 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd(SHSE:603439) from Wang Huiying.	30/23/30	CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Guizhou Sanli Pharmaceutical Co.,Ltd agreed to acquire a stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian	23/23/23	CI
Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million	22/23/22	CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. entered into 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd from Wang Huiying for CNY 322.875 million.	31/23/31	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Guizhou Sanli Pharma Sees Up to 42.5% Jump in 2022 Profit	09/23/09	MT
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd signed framework agreement to acquire 51% stake in Guizhou Haosite Biotechnology Co., Ltd. from Zhao Guofu.	28/22/28	CI
GuiZhou SanLi Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	21/22/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GuiZhou SanLi Pharmaceutical Co.,Ltd

Equities

603439

CNE1000040B4

Highlights

Filters